Intensive Care Med
Intensive Care Medicine
0342-4642
1432-1238
Springer-Verlag
Berlin/Heidelberg


2039828
17646966
791
10.1007/s00134-007-0791-z
Review


Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients

Trof
R. J.

+31-20-4443309
+31-20-4442392
r.trof@vumc.nl

1

Beishuizen
A.

1

Debets-Ossenkopp
Y. J.

2

Girbes
A. R. J.

1

Groeneveld
A. B. J.

1

1
Department of Intensive Care, VU Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands 
2
Department of Clinical Microbiology and Infection Control, VU Medical Centre, Amsterdam, The Netherlands 

24
7
2007

10
2007

33
10
1694
1703
18
7
2006

28
6
2007


© Springer-Verlag 2007

Aspergillus
Aspergillus
 PCR in serum, in whom voriconazole is the drug of choice. The benefit of combination antifungal therapy lacks sufficient evidence so far, but this treatment might be considered in patients with breakthrough infections or refractory disease.

Keywords
Invasive pulmonary aspergillosis
Non-neutropenic critically ill
Antifungal therapy
Serological markers

issue-copyright-statement
© Springer-Verlag 2007




Introduction
1
6
2
3
6
4
5
]. This high mortality is at least partially related to difficulties in timely diagnosis, caused by insensitive and non-specific clinical signs and lack of unequivocal diagnostic criteria.
In this review, we will describe the pathophysiological mechanisms and risk factors for IPA in non-neutropenic critically ill patients, limitations and advances in the diagnostic process, and alterations in treatment with antifungal therapy. A Medline/PubMed search was performed for all articles about IPA in critically ill patients in relation to risk factors, diagnosis and antifungal therapy. All publication types of human studies in the English language were searched and an extraction of relevant articles was made for the purpose of this narrative review.

Pathophysiological mechanisms and risk factors
Aspergillus
Aspergillus
Aspergillus
fumigatus
Aspergillus flavus, Aspergillus terreus
Aspergillus niger
Aspergillus nidulans
7
Aspergillus
Aspergillus
8
9
10
].
Aspergillus
11
Aspergillus
12
13
12
14
15
].
16
17
Aspergillus
17
18
19
20
23
Aspergillus fumigatus
21
1
24
26
27
1
4
28
32
2
31
33
2
4
34
8
35
4
36
38
1
Aspergillus
3
31
Table 1
Risk factors for IPA in non-neutropenic critically ill patients in the ICU

Risk factor
Reference


COPD in combination with prolonged corticosteroid use
1
24
26
]

High-dose systemic corticosteroids > 3 weeks (e. g. prednisone equivalent
    > 20 mg/day)
2
31
33
]

Chronic renal failure with RRT
8
35
]

Liver cirrhosis/acute hepatic failure
2
4
34
]

Near-drowning
4
36
38
]

Diabetes mellitus
2
3
31
33
]



COPD
RRT
,
 renal replacement therapy




Diagnostic features
39
]. However, these guidelines are intended for use in clinical trials and for epidemiologic research and, moreover, are focused on patients with classical risk factors such as neutropenia, malignancies and after haematopoietic stem cell transplantation, and it may not be possible to extrapolate them to the non-neutropenic critically ill patient.
1
39
Aspergillus
Aspergillus
32
6
7
39
2
6
40
41
2
6
40
40
42
Aspergillus, Fusarium and Scedosporium
Mucorales
Mucorales
Aspergillus, Fusarium and Scedosporium
Aspergillus fumigatus
43
Aspergillus
-related tracheobronchitis.
44
50
51
47
3
6
52
]. Due to the high tropism for blood vessels, IPA might be complicated by localisations in the central nervous system. Therefore, in patients with documented or highly suspected IPA, CT scanning or magnetic resonance imaging (MRI) of the brain should be considered to exclude dissemination to the brain.
Aspergillus
Aspergillus
Aspergillus
53
Aspergillus
54
57
Aspergillus
53
54
58
59
62
63
64
67
63
68
69
53
54
Aspergillus
39
53
54
70
72
3
]. Thus, it has to be stressed that the available data from patients with (haematological) malignancies and after solid organ transplantation can not be extrapolated to the critically ill patient in general. In the meantime, due to lack of more reliable, non-invasive diagnostic tests, the GM assay could be used as an additive tool in the diagnostic work-up of IPA.
Aspergillus
Candida
73
33
74
]. Hence, the usefulness of 1,3-β-glucan in the diagnosis of IPA has to be further evaluated.
75
79
80
81
Aspergillus
78
82
].
Aspergillus
Aspergillus
 PCR, in a patient with persisting pulmonary infection who carries one or more risk factors, is highly indicative for IPA and might justify treatment with antifungal therapy.

Antifungal therapy
83
84
85
86
87
88
]. However, lipid formulations are more expensive, and the initial use of higher doses does not improve efficacy and is associated with greater toxicity than lower doses, which suggests that high doses may not be routinely warranted.
Aspergillus
89
Aspergillus
fumigatus
90
91
92
93
93
94
95
96
96
96
97
96
98
99
43
100
101
].
102
]. Posaconazole is, however, only available for oral administration, which makes it probably less applicable in critically ill patients who are susceptible to impaired drug absorption in the digestive tract.
103
Candida
Aspergillus
104
105
]. However, prospective randomised clinical trials aimed at the treatment of IPA in (non-neutropenic) critically ill patients are lacking.
2
Table 2
Treatment options with antifungal drugs for IPA in critically ill patients in the ICU

Setting
First choice
Alternatives


Primary therapy of IPA
Voriconazole 6 mg/kg q 12 h i. v. on day 1, then 4 mg/kg
    q 12 h i. v.
Liposomal amphotericin B 3-5 mg/kg/day i. v.


or
or


a

Amphotericin B deoxycholate 1 mg/kg/day i. v.



or



b




a
b
 In patients with moderate to severe hepatic failure, dose reduction
 is recommended to 35 mg/day i. v.




Combination therapy
106
107
] empirical administration of combination antifungal regiments for proven or probable IPA may be an important strategy to improve outcome.
108
108
109
]. These subtle effects could be enhanced when one antifungal is applied together with a second drug, resulting in synergy. Conversely, the combination could act antagonistically, e. g. when one antifungal agent affects the targets of the other one.
110
113
114
115
116
].

Conclusion
Aspergillus
Aspergillus
Aspergillus
 PCR are present, accompanied with one of those risk factors for which voriconazole appears to be the first-line treatment. Combination therapy might be considered in breakthrough infections with moulds or yeasts or in refractory disease, although clear evidence is lacking.


References
1.
Bulpa
PA

Dive
AM

Garrino
MG

Delos
MA

Gonzalez
MR

Evrard
PA

Glupczynski
Y

Installe
EJ


Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?
Intensive Care Med
2001
27
59
67

11280674


2.
Garnacho-Montero
J

Amaya-Villar
R

Ortiz-Leyba
C

Leon
C

Alvarez-Lerma
F

Nolla-Salas
J

Iruretagoyena
JR

Barcenilla
F


Aspergillus
 spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome
Crit Care
2005
9
R191
R199

15987390


3.
Meersseman
W

Vandecasteele
SJ

Wilmer
A

Verbeken
E

Peetermans
WE

Van
WE


Invasive aspergillosis in critically ill patients without malignancy
Am J Respir Crit Care Med
2004
170
621
625

15229094


4.
Vandewoude
K

Blot
S

Benoit
D

Depuydt
P

Vogelaers
D

Colardyn
F


Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality
Acta Clin Belg
2004
59
251
257

15641394


5.
Vandewoude
KH

Blot
SI

Benoit
D

Colardyn
F

Vogelaers
D


Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence
J Hosp Infect
2004
56
269
276

15066736


6.
Vandewoude
KH

Blot
SI

Depuydt
P

Benoit
D

Temmerman
W

Colardyn
F

Vogelaers
D


Aspergillus
 isolation from respiratory tract samples in critically ill patients
Crit Care
2006
10
R31

16507158


7.
Perfect
JR

Cox
GM

Lee
JY

Kauffman
CA

Repentigny
L

Chapman
SW

Morrison
VA

Pappas
P

Hiemenz
JW

Stevens
DA


Aspergillus
 species: a hospital-based survey of aspergillosis
Clin Infect Dis
2001
33
1824
1833

11692293


8.
Sessa
A

Meroni
M

Battini
G

Pitingolo
F

Giordano
F

Marks
M

Casella
P


Aspergillus fumigatus
 infection among patients in a renal unit?
Nephrol Dial Transplant
1996
11
1322
1324

8672030


9.
Anaissie
EJ

Costa
SF


Nosocomial aspergillosis is waterborne
Clin Infect Dis
2001
33
1546
1548

11568850


10.
Anaissie
EJ

Stratton
SL

Dignani
MC

Summerbell
RC

Rex
JH

Monson
TP

Spencer
T

Kasai
M

Francesconi
A

Walsh
TJ


Aspergillus
 species recovered from a hospital water system: a 3-year prospective study
Clin Infect Dis
2002
34
780
789

11850861


11.
Reichenberger
F

Habicht
JM

Gratwohl
A

Tamm
M


Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients
Eur Respir J
2002
19
743
755

11999005


12.
Cenci
E

Perito
S

Enssle
KH

Mosci
P

Latge
JP

Romani
L

Bistoni
F


Th1 and Th2 cytokines in mice with invasive aspergillosis
Infect Immun
1997
65
564
570

9009314


13.
Cenci
E

Mencacci
A

Fe
DC

Del
SG

Mosci
P

Montagnoli
C

Bacci
A

Romani
L


Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis
J Infect Dis
1998
178
1750
1760

9815229


14.
Cenci
E

Mencacci
A

Del
SG

Bacci
A

Montagnoli
C

d'Ostiani
CF

Mosci
P

Bachmann
M

Bistoni
F

Kopf
M

Romani
L


Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses
J Infect Dis
1999
180
1957
1968

10558953


15.
Cenci
E

Mencacci
A

Bacci
A

Bistoni
F

Kurup
VP

Romani
L


T cell vaccination in mice with invasive pulmonary aspergillosis
J Immunol
2000
165
381
388

10861075


16.
Lederer
JA

Rodrick
ML

Mannick
JA


The effects of injury on the adaptive immune response
Shock
1999
11
153
159

10188766


17.
Hartemink
KJ

Paul
MA

Spijkstra
JJ

Girbes
AR

Polderman
KH


Immunoparalysis as a cause for invasive aspergillosis?
Intensive Care Med
2003
29
2068
2071

12768234


18.
Maertens
J

Vrebos
M

Boogaerts
M


Assessing risk factors for systemic fungal infections
Eur J Cancer Care
2001
10
56
62

Maertens J, Vrebos M, Boogaerts M (2001) Assessing risk factors for systemic fungal infections. Eur J Cancer Care 10:56–62 

19.
Kwoun
MO

Ling
PR

Lydon
E

Imrich
A

Qu
Z

Palombo
J

Bistrian
BR


Immunologic effects of acute hyperglycemia in nondiabetic rats
J Parenter Enteral Nutr
1997
21
91
95

Kwoun MO, Ling PR, Lydon E, Imrich A, Qu Z, Palombo J, Bistrian BR (1997) Immunologic effects of acute hyperglycemia in nondiabetic rats. J Parenter Enteral Nutr 21:91–95 

20.
Diamond
RD


Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones
J Infect Dis
1983
147
160

6822752


21.
Ng
TT

Robson
GD

Denning
DW


Aspergillus
 spp.: implications for pathogenesis
Microbiology
1994
140
2475
2479

7952197


22.
Roilides
E

Uhlig
K

Venzon
D

Pizzo
PA

Walsh
TJ


Aspergillus fumigatus
 hyphae by granulocyte colony-stimulating factor and gamma interferon
Infect Immun
1993
61
4870
4877

7691757


23.
Schaffner
A


Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon
J Clin Invest
1985
76
1755
1764

3932471


24.
Crean
JM

Niederman
MS

Fein
AM

Feinsilver
SH


Aspergillus
 pneumonia: a complication of short-term corticosteroid therapy
Crit Care Med
1992
20
148
150

1729033


25.
Pittet
D

Huguenin
T

Dharan
S

Sztajzel-Boissard
J

Ducel
G

Thorens
JB

Auckenthaler
R

Chevrolet
JC


Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
1996
154
541
544

8756836


26.
Rello
J

Esandi
ME

Mariscal
D

Gallego
M

Domingo
C

Valles
J


Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review
Clin Infect Dis
1998
26
1473
1475

9636889


27.
Maki
DG


Risk factors for nosocomial infection in intensive care. ‘Devices vs nature’ and goals for the next decade
Arch Intern Med
1989
149
30
35

2643417


28.
Ader
F

Nseir
S

Le
BR

Leroy
S

Tillie-Leblond
I

Marquette
CH

Durocher
A


Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen
Clin Microbiol Infect
2005
11
427
429

15882191


29.
Ader
F

Nseir
S

Guery
B

Tillie-Leblond
I


Acute invasive pulmonary aspergillosis in chronic lung disease – a review
Rev Mal Respir
2006
23
S11
20

Ader F, Nseir S, Guery B, Tillie-Leblond I (2006) Acute invasive pulmonary aspergillosis in chronic lung disease – a review. Rev Mal Respir 23:S11–20 

30.
Chen
KY

Ko
SC

Hsueh
PR

Luh
KT

Yang
PC


Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors
Chest
2001
120
177
184

11451835


31.
Khasawneh
F

Mohamad
T

Moughrabieh
MK

Lai
Z

Ager
J

Soubani
AO


Aspergillus
 in critically ill patients: a potential marker of poor outcome
J Crit Care
2006
21
322
327

17175418


32.
Soubani
AO

Khanchandani
G

Ahmed
HP


Aspergillus
 culture in elderly hospitalized patients
Eur J Clin Microbiol Infect Dis
2004
23
491
494

15141337


33.
Vandewoude
KH

Vogelaers
D

Blot
SI


Aspergillosis in the ICU – the new 21st century problem?
Med Mycol
2006
44
S71
76

Vandewoude KH, Vogelaers D, Blot SI (2006) Aspergillosis in the ICU – the new 21st century problem? Med Mycol 44:S71–76 

34.
Prodanovic
H

Cracco
C

Massard
J

Barrault
C

Thabut
D

Duguet
A

Datry
A

Derenne
JP

Poynard
T

Similowski
T


Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
BMC Gastroenterol
2007
7
2

17266747


35.
Sahlen
AO

Suvarna
SK

Wilkie
ME


A case of invasive pulmonary aspergillosis in renal failure
Nephrol Dial Transplant
2004
19
2687

15388843


36.
Maaten
JC

Golding
RP

Strack van Schijndel
RJ

Thijs
LG


Disseminated aspergillosis after near-drowning
Neth J Med
1995
47
21
24

7651562


37.
Vieira
DF

Saene
HK

Miranda
DR


Invasive pulmonary aspergillosis after near-drowning
Intensive Care Med
1984
10
203
204

6381566


38.
Leroy
P

Smismans
A

Seute
T


Invasive pulmonary and central nervous system aspergillosis after near-drowning of a child: case report and review of the literature
Pediatrics
2006
118
e509
e513

16864641


39.
Ascioglu
S

Rex
JH

Pauw
B

Bennett
JE

Bille
J

Crokaert
F

Denning
DW

Donnelly
JP

Edwards
JE

Erjavec
Z

Fiere
D

Lortholary
O

Maertens
J

Meis
JF

Patterson
TF

Ritter
J

Selleslag
D

Shah
PM

Stevens
DA

Walsh
TJ


Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus
Clin Infect Dis
2002
34
7
14

11731939


40.
Levy
H

Horak
DA

Tegtmeier
BR

Yokota
SB

Forman
SJ


The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis
Respir Med
1992
86
243
248

1620912


41.
Cahill
BC

Hibbs
JR

Savik
K

Juni
BA

Dosland
BM

Edin-Stibbe
C

Hertz
MI


Aspergillus
 airway colonization and invasive disease after lung transplantation
Chest
1997
112
1160
1164

9367451


42.
Andreas
S

Heindl
S

Wattky
C

Moller
K

Ruchel
R


Diagnosis of pulmonary aspergillosis using optical brighteners
Eur Respir J
2000
15
407
411

10706512


43.
Verweij
PE

Mellado
E

Melchers
WJ


Multiple-triazole-resistant aspergillosis
N Engl J Med
2007
356
1481
1483

17409336


44.
Collins
J


CT signs and patterns of lung disease
Radiol Clin North Am
2001
39
1115
1135

11699664


45.
Greene
R


The radiological spectrum of pulmonary aspergillosis
Med Mycol
2005
43
S147
S154

16110807


46.
Horger
M

Einsele
H

Schumacher
U

Wehrmann
M

Hebart
H

Lengerke
C

Vonthein
R

Claussen
CD

Pfannenberg
C


Invasive pulmonary aspergillosis: frequency and meaning of the “hypodense sign” on unenhanced CT
Br J Radiol
2005
78
697
703

16046420


47.
Kami
M

Kishi
Y

Hamaki
T

Kawabata
M

Kashima
T

Masumoto
T

Oki
Y

Tanaka
Y

Sawada
S

Machida
U

Ohtomo
K

Kanda
Y

Hirai
H

Mutou
Y


The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients
Mycoses
2002
45
287
294

12572717


48.
Lee
YR

Choi
YW

Lee
KJ

Jeon
SC

Park
CK

Heo
JN


CT halo sign: the spectrum of pulmonary diseases
Br J Radiol
2005
78
862
865

16110114


49.
Pasmans
HL

Loosveld
OJ

Schouten
HC

Thunnissen
F

Engelshoven
JM


Invasive aspergillosis in immunocompromised patients: findings on plain film and (HR)CT
Eur J Radiol
1992
14
37
40

1563402


50.
Won
HJ

Lee
KS

Cheon
JE

Hwang
JH

Kim
TS

Lee
HG

Han
J


Invasive pulmonary aspergillosis: prediction at thin-section CT in patients with neutropenia – a prospective study
Radiology
1998
208
777
782

9722859


51.
Pinto
PS


The CT halo sign
Radiology
2004
230
37
40

Pinto PS (2004) The CT halo sign. Radiology 230:37–40 

52.
Greene RE, Schlamm HT, Stark P, Oestmann JW, Troke P, Patterson TF, Herbrecht R, Wingard J, Bennett JE, Lortholary J (2003) Radiological findings in acute invasive pulmonary aspergillosis: utility and reliability of halo sign and air crescent sign for diagnosis and treatment of invasive pulmonary aspergillosis in high-risk patients. Abstract European Congress of Microbiology and Infectious Diseases, 13th annual meeting

53.
Maertens
J

Verhaegen
J

Lagrou
K

Van
EJ

Boogaerts
M


Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation
Blood
2001
97
1604
1610

11238098


54.
Maertens
J

Van
EJ

Verhaegen
J

Verbeken
E

Verschakelen
J

Boogaerts
M


Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients
J Infect Dis
2002
186
1297
1306

12402199


55.
Sulahian
A

Boutboul
F

Ribaud
P

Leblanc
T

Lacroix
C

Derouin
F


Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study
Cancer
2001
91
311
318

11180076


56.
Herbrecht
R

Letscher-Bru
V

Oprea
C

Lioure
B

Waller
J

Campos
F

Villard
O

Liu
KL

Natarajan-Ame
S

Lutz
P

Dufour
P

Bergerat
JP

Candolfi
E


Aspergillus
 galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients
J Clin Oncol
2002
20
1898
1906

11919250


57.
Pinel
C

Fricker-Hidalgo
H

Lebeau
B

Garban
F

Hamidfar
R

Ambroise-Thomas
P

Grillot
R


Aspergillus fumigatus
 galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis
J Clin Microbiol
2003
41
2184
2186

12734275


58.
Pfeiffer
CD

Fine
JP

Safdar
N


Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis
Clin Infect Dis
2006
42
1417
1427

16619154


59.
Sanguinetti
M

Posteraro
B

Pagano
L

Pagliari
G

Fianchi
L

Mele
L

La
SM

Franco
A

Fadda
G


Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis
J Clin Microbioll
2003
41
3922
3925

Sanguinetti M, Posteraro B, Pagano L, Pagliari G, Fianchi L, Mele L, La SM, Franco A, Fadda G (2003) Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbioll 41:3922–3925 

60.
Musher
B

Fredricks
D

Leisenring
W

Balajee
SA

Smith
C

Marr
KA


Aspergillus
 galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid
J Clin Microbiol
2004
42
5517
5522

15583275


61.
Seyfarth
HJ

Nenoff
P

Winkler
J

Krahl
R

Haustein
UF

Schauer
J


Aspergillus
 detection in bronchoscopically acquired material. Significance and interpretation
Mycoses
2001
44
356
360

11766098


62.
Clancy
CJ

Jaber
RA

Leather
HL

Wingard
JR

Staley
B

Wheat
LJ

Cline
CL

Rand
KH

Schain
D

Baz
M

Nguyen
MH


Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients
J Clin Microbiol
2007
45
1759
1765

17428933


63.
Ansorg
R

Boom
R

Rath
PM


Aspergillus
 galactomannan antigen in foods and antibiotics
Mycoses
1997
40
353
357

9470421


64.
Viscoli
C

Machetti
M

Cappellano
P

Bucci
B

Bruzzi
P

Lint
MT

Bacigalupo
A


Aspergillus
 test results for patients receiving piperacillin–tazobactam
Clin Infect Dis
2004
38
913
916

14999640


65.
Adam
O

Auperin
A

Wilquin
F

Bourhis
JH

Gachot
B

Chachaty
E


Aspergillus
 galactomannan antigen test results for patients with hematological malignancies
Clin Infect Dis
2004
38
917
920

14999641


66.
Mattei
D

Rapezzi
D

Mordini
N

Cuda
F

Lo
NC

Musso
M

Arnelli
A

Cagnassi
S

Gallamini
A


Aspergillus
 galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin–clavulanic acid treatment
J Clin Microbiol
2004
42
5362
5363

15528743


67.
Sulahian
A

Touratier
S

Ribaud
P


Aspergillus
 antigenemia related to concomitant administration of piperacillin and tazobactam
N Engl J Med
2003
349
2366
2367

14668472


68.
Becker
MJ

De
MS

Fens
MH

Verbrugh
HA

Bakker-Woudenberg
IA


Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis
J Antimicrob Chemother
2003
52
428
434

12917249


69.
Marr
KA

Laverdiere
M

Gugel
A

Leisenring
W


Aspergillus
 galactomannan enzyme immunoassay
Clin Infect Dis
2005
40
1762
1769

15909264


70.
Verweij
PE

Latge
JP

Rijs
AJ

Melchers
WJ

Pauw
BE

Hoogkamp-Korstanje
JA

Meis
JF


Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies
J Clin Microbiol
1995
33
3150
3153

8586691


71.
Maertens
J

Theunissen
K

Verbeken
E

Lagrou
K

Verhaegen
J

Boogaerts
M

Eldere
JV


Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients
Br J Haematol
2004
126
852
860

15352990


72.
Salonen
J

Lehtonen
OP

Terasjarvi
MR

Nikoskelainen
J


Aspergillus
 antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome
Scand J Infect Dis
2000
32
485
490

11055651


73.
Ostrosky-Zeichner
L

Alexander
BD

Kett
DH

Vazquez
J

Pappas
PG

Saeki
F

Ketchum
PA

Wingard
J

Schiff
R

Tamura
H

Finkelman
MA

Rex
JH


Multicenter clinical evaluation of the (1–> 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans
Clin Infect Dis
2005
41
654
659

16080087


74.
Digby
J

Kalbfleisch
J

Glenn
A

Larsen
A

Browder
W

Williams
D


Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients
Clin Diagn Lab Immunol
2003
10
882
885

12965921


75.
Skladny
H

Buchheidt
D

Baust
C

Krieg-Schneider
F

Seifarth
W

Leib-Mosch
C

Hehlmann
R


Aspergillus
 species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR
J Clin Microbiol
1999
37
3865
3871

10565898


76.
Bretagne
S

Costa
JM

Marmorat-Khuong
A

Poron
F

Cordonnier
C

Vidaud
M

Fleury-Feith
J


Aspergillus
 species DNA in bronchoalveolar lavage samples by competitive PCR
J Clin Microbiol
1995
33
1164
1168

7615723


77.
Raad
I

Hanna
H

Sumoza
D

Albitar
M


Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients
Cancer
2002
94
1032
1036

11920473


78.
Raad
I

Hanna
H

Huaringa
A

Sumoza
D

Hachem
R

Albitar
M


Aspergillus
 in BAL
Chest
2002
121
1171
1176

11948049


79.
Buchheidt
D

Baust
C

Skladny
H

Baldus
M

Brauninger
S

Hehlmann
R


Aspergillus
 species in bronchoalveolar lavage samples of neutropenic patients
Br J Haematol
2002
116
803
811

11886384


80.
White
PL

Linton
CJ

Perry
MD

Johnson
EM

Barnes
RA


The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting
Clin Infect Dis
2006
42
479
486

16421791


81.
Hope
WW

Walsh
TJ

Denning
DW


Laboratory diagnosis of invasive aspergillosis
Lancet Infect Dis
2005
5
609
622

16183515


82.
Garcia
ME

Blanco
JL

Caballero
J

Gargallo-Viola
D


Anticoagulants interfere with PCR used to diagnose invasive aspergillosis
J Clin Microbiol
2002
40
1567
1568

11923400


83.
Ostrosky-Zeichner
L

Marr
KA

Rex
JH

Cohen
SH


Amphotericin B: time for a new “gold standard”
Clin Infect Dis
2003
37
415
425

12884167


84.
Wingard
JR

Kubilis
P

Lee
L

Yee
G

White
M

Walshe
L

Bowden
R

Anaissie
E

Hiemenz
J

Lister
J


Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
Clin Infect Dis
1999
29
1402
1407

10585786


85.
Eriksson
U

Seifert
B

Schaffner
A


Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial
BMJ
2001
322
579
582

11238151


86.
Imhof
A

Walter
RB

Schaffner
A


Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study
Clin Infect Dis
2003
36
943
951

12684904


87.
Andes
D

Stamsted
T

Conklin
R


Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Antimicrob Agents Chemother
2001
45
922
926

11181381


88.
Walsh
TJ

Finberg
RW

Arndt
C

Hiemenz
J

Schwartz
C

Bodensteiner
D

Pappas
P

Seibel
N

Greenberg
RN

Dummer
S

Schuster
M

Holcenberg
JS


Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group
N Engl J Med
1999
340
764
771

10072411


89.
Marr
KA

Crippa
F

Leisenring
W

Hoyle
M

Boeckh
M

Balajee
SA

Nichols
WG

Musher
B

Corey
L


Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
Blood
2004
103
1527
1533

14525770


90.
Denning
DW

Venkateswarlu
K

Oakley
KL

Anderson
MJ

Manning
NJ

Stevens
DA

Warnock
DW

Kelly
SL


Aspergillus fumigatus

Antimicrob Agents Chemother
1997
41
1364
1368

9174200


91.
Herbrecht
R

Denning
DW

Patterson
TF

Bennett
JE

Greene
RE

Oestmann
JW

Kern
WV

Marr
KA

Ribaud
P

Lortholary
O

Sylvester
R

Rubin
RH

Wingard
JR

Stark
P

Durand
C

Caillot
D

Thiel
E

Chandrasekar
PH

Hodges
MR

Schlamm
HT

Troke
PF


Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
N Engl J Med
2002
347
408
415

12167683


92.
Bohme
A

Ruhnke
M

Buchheidt
D

Karthaus
M

Einsele
H

Guth
S

Heussel
G

Heussel
CP

Junghanss
C

Kern
WK

Kubin
T

Maschmeyer
G

Sezer
O

Silling
G

Sudhoff
T

Szelenyi
DH

Ullmann
AJ


Treatment of fungal infections in hematology and oncology – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Ann Hematol
2003
82
S133
S140

13680170


93.
Theuretzbacher
U

Ihle
F

Derendorf
H


Pharmacokinetic/pharmacodynamic profile of voriconazole
Clin Pharmacokinet
2006
45
649
663

16802848


94.
Saari
TI

Laine
K

Leino
K

Valtonen
M

Neuvonen
PJ

Olkkola
KT


Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
Clin Pharmacol Ther
2006
79
362
370

16580904


95.
Scherpbier
HJ

Hilhorst
MI

Kuijpers
TW


Liver failure in a child receiving highly active antiretroviral therapy and voriconazole
Clin Infect Dis
2003
37
828
830

12955645


96.
Mach
MA

Burhenne
J

Weilemann
LS


Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy
BMC Clin Pharmacol
2006
6
6

16981986


97.
Smith
J

Safdar
N

Knasinski
V

Simmons
W

Bhavnani
SM

Ambrose
PG

Andes
D


Voriconazole therapeutic drug monitoring
Antimicrob Agents Chemother
2006
50
1570
1572

16569888


98.
Robatel
C

Rusca
M

Padoin
C

Marchetti
O

Liaudet
L

Buclin
T


Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient
J Antimicrob Chemother
2004
54
269
270

15175271


99.
Trotman
RL

Williamson
JC

Shoemaker
DM

Salzer
WL


Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy
Clin Infect Dis
2001
41
1159
1166

16163635


100.
Imhof
A

Balajee
SA

Fredricks
DN

Englund
JA

Marr
KA


Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole
Clin Infect Dis
2004
39
743
746

15356792


101.
Marty
FM

Cosimi
LA

Baden
LR


Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants
N Engl J Med
2004
350
950
952

14985500


102.
Walsh
TJ

Raad
I

Patterson
TF

Chandrasekar
P

Donowitz
GR

Graybill
R

Greene
RE

Hachem
R

Hadley
S

Herbrecht
R

Langston
A

Louie
A

Ribaud
P

Segal
BH

Stevens
DA

Burik
JA

White
CS

Corcoran
G

Gogate
J

Krishna
G

Pedicone
L

Hardalo
C

Perfect
JR


Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
Clin Infect Dis
2007
44
2
12

17143808


103.
Denning
DW


Echinocandin antifungal drugs
Lancet
2003
362
1142
1151

14550704


104.
Maertens
J

Raad
I

Petrikkos
G

Boogaerts
M

Selleslag
D

Petersen
FB

Sable
CA

Kartsonis
NA

Ngai
A

Taylor
A

Patterson
TF

Denning
DW

Walsh
TJ


Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
Clin Infect Dis
2004
39
1563
1571

15578352


105.
Walsh
TJ

Teppler
H

Donowitz
GR

Maertens
JA

Baden
LR

Dmoszynska
A

Cornely
OA

Bourque
MR

Lupinacci
RJ

Sable
CA

Pauw
BE


Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
N Engl J Med
2004
351
1391
1402

15459300


106.
Lin
SJ

Schranz
J

Teutsch
SM


Aspergillosis case-fatality rate: systematic review of the literature
Clin Infect Dis
2001
32
358
366

11170942


107.
Patterson
TF

Kirkpatrick
WR

White
M

Hiemenz
JW

Wingard
JR

Dupont
B

Rinaldi
MG

Stevens
DA

Graybill
JR


Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group
Medicine (Baltimore)
2000
79
250
260

10941354


108.
Lewis
RE

Kontoyiannis
DP


Rationale for combination antifungal therapy
Pharmacotherapy
2001
21
149S
164S

11501988


109.
Kumar
S

Chakrabarti
R


Amphotericin B both inhibits and enhances T-cell proliferation: inhibitory effect is mediated through H(2)O(2) production via cyclooxygenase pathway by macrophages
J Cell Biochem
2000
77
361
371

10760945


110.
Aliff
TB

Maslak
PG

Jurcic
JG

Heaney
ML

Cathcart
KN

Sepkowitz
KA

Weiss
MA


Aspergillus
 pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin
Cancer
2003
97
1025
1032

12569602


111.
Kontoyiannis
DP

Hachem
R

Lewis
RE

Rivero
GA

Torres
HA

Thornby
J

Champlin
R

Kantarjian
H

Bodey
GP

Raad
II


Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies
Cancer
2003
98
292
299

12872348


112.
Thiebaut
A

Antal
D

Breysse
MC


Refractory invasive fungal infections in patients with hematological malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B
2002
San Diego, California
In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy

Thiebaut A, Antal D, Breysse MC (2002) Refractory invasive fungal infections in patients with hematological malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California 

113.
Singh
N

Limaye
AP

Forrest
G

Safdar
N

Munoz
P

Pursell
K

Houston
S

Rosso
F

Montoya
JG

Patton
P

Del
BR

Aguado
JM

Fisher
RA

Klintmalm
GB

Miller
R

Wagener
MM

Lewis
RE

Kontoyiannis
DP

Husain
S


Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study
Transplantation
2006
81
320
326

16477215


114.
Antoniadou
A

Kontoyiannis
DP


Status of combination therapy for refractory mycoses
Curr Opin Infect Dis
2003
16
539
545

14624103


115.
Fluckiger
U

Marchetti
O

Bille
J

Eggimann
P

Zimmerli
S

Imhof
A

Garbino
J

Ruef
C

Pittet
D

Tauber
M

Glauser
M

Calandra
T


Treatment options of invasive fungal infections in adults – review
Swiss Med Wkly
2006
136
447
463

16937323


116.
Kontoyiannis
DP

Lewis
RE


Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far
Drug Resist Updat
2003
6
257
269

14643296



http://dx.doi.org/10.1007/s00134-007-0792-y
.




